GABRP and cancer: Throughout cancer staging, TCGA database showed consistent reduction in expression levels of GABRA2, GABRE, GABRG1 and GABRP by up to 32.7%, 18.7%, 15.4% and 5.9%, respectively (Fig. 3B, K, L, O).